EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amoeboid–mesenchymal transition and the proteolytic control of cancer invasion plasticity

Adam W Olson iD, Jonathan Li iD, Xiao-Yan Li iD, Lana King iD, Long Jiang, Kalins Banerjee iD, Atticus J McCoy iD, Mahnoor N Gondal, Arul M Chinnaiyan iD, Dorraya El-Ashry, Evan T Keller iD, Andrew J Putnam iD und 1 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2520717123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Adam W Olson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Department, Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109. Hauptthemen laut MEDLINE: Breast Neoplasms, Epithelial-Mesenchymal Transition, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NHLBI NIH HHS, HHS | National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasion plasticity allows malignant cells to toggle between collective, mesenchymal, and amoeboid phenotypes while traversing extracellular matrix (ECM) barriers. Current dogma holds that collective and mesenchymal invasion programs trigger the mobilization of proteinases that digest structural barriers dominated by type I collagen, while amoeboid activity allows cancer cells to marshal mechanical forces to traverse tissues independently of ECM proteolysis. Here, we use cancer spheroid-3-dimensional matrix models, single-cell RNA sequencing, and human tissue explants to identify the mechanisms controlling mesenchymal versus amoeboid invasion. Unexpectedly, collective/mesenchymal- and amoeboid-type invasion programs—though distinct—are each characterized by active tunneling through ECM barriers, with expression of matrix-degradative metalloproteinases. CRISPR/Cas9-mediated targeting of a single membrane-anchored collagenase, MMP14/MT1-MMP, ablates tissue-invasive activity while coregulating cancer cell transcriptional programs. Though changes in matrix architecture, nuclear rigidity, and metabolic stress as well as the presence of cancer-associated fibroblasts are proposed to support amoeboid activity, none of these changes restore invasive activity of MMP14-targeted cancer cells. While a requirement for MMP14 is bypassed in low-density collagen hydrogels, invasion by the proteinase-deleted cells is associated with nuclear envelope and DNA damage, highlighting a proteolytic requirement for maintaining nuclear integrity. Nevertheless, when cancer cells confront explants of live human breast tissue, MMP14 is again required to support invasive activity. Corroborating these results, spatial transcriptomic and immunohistological analyses of human breast cancers identified MMP14 expression in tissue-infiltrating carcinoma cells that were further juxtaposed with proteolyzed type I collagen fragments, underlining the pathophysiologic importance of this proteinase in directing invasive activity in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEpithelial-Mesenchymal TransitionNeoplasmsHumansNeoplasm InvasivenessProteolysisExtracellular MatrixMatrix Metalloproteinase 14Cell Line, TumorFemaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

amoeboidcancerinvasionproteinase

Substanzen

Matrix Metalloproteinase 14MMP14 protein, human

Autor:innen und Institutionen

  • Cancer Biology Department, Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109.
  • Department of Urology, Single Cell Spatial Analysis Program and Biointerfaces Institute, University of Michigan Medical School, Ann Arbor, MI 48109.
  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109.
  • Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109.
  • Michigan Center for Translational Pathology, Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109.
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.

ORCID-Profile: Adam W Olson, Jonathan Li, Xiao-Yan Li, Lana King, Kalins Banerjee, Atticus J McCoy, Arul M Chinnaiyan, Evan T Keller, Andrew J Putnam, Stephen J Weiss

Förderung

  • HHS | NIH | National Cancer Institute (NCI)
  • NHLBI NIH HHS
  • HHS | National Institutes of Health (NIH)
  • Breast Cancer Research Foundation (BCRF)
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)

Zitieren

APA

Olson, A. W., Li, J., Li, X. Y., King, L., Jiang, L., Banerjee, K., McCoy, A. J., Gondal, M. N., Chinnaiyan, A. M., El-Ashry, D., Keller, E. T., Putnam, A. J., & Weiss, S. J. (2026). Amoeboid–mesenchymal transition and the proteolytic control of cancer invasion plasticity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2520717123

Vancouver

Olson AW, Li J, Li XY, King L, Jiang L, Banerjee K, et al. Amoeboid–mesenchymal transition and the proteolytic control of cancer invasion plasticity. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2520717123

BibTeX
@article{Olson2026,
  author = {Olson, Adam W and Li, Jonathan and Li, Xiao-Yan and King, Lana and Jiang, Long and Banerjee, Kalins and McCoy, Atticus J and Gondal, Mahnoor N and Chinnaiyan, Arul M and El-Ashry, Dorraya and Keller, Evan T and Putnam, Andrew J and Weiss, Stephen J},
  title = {Amoeboid–mesenchymal transition and the proteolytic control of cancer invasion plasticity},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2520717123}
}
Kostenlos starten →